Compare

Melanotan I vs Melanotan II

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Melanotan I

1159 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 43% · Mixed 42% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Lean mass
150
Joint comfort
51
Recovery
106
Digestive comfort
68
Skin appearance
176

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Appetite loss
66
Injection site reaction
131
Anxiety
71
Flushing
64
Headache
176

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.1–5 mg

0.1–0.2 mg
3
0.2–0.4 mg
10
0.4–0.6 mg
17
0.6–1 mg
24
1–2 mg
21
2–3 mg
16
3–5 mg
6

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing43stacking11side effects9melanotan i17

How repeat users are trending

Among repeat reporters, 53% said they felt similar to their last entry, 29% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 15 days · Based on 255 repeat reporters

Melanotan II

1450 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 64% · Mixed 18% · Unfavorable overall 18%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
-167
Focus
12
Sleep quality
-101
Lean mass
-48
Joint comfort
-18

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
-71
Nausea
-89
Water retention
-136
Appetite loss
-52
Injection site reaction
-19

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.05–3 mg

0.05–0.1 mg
2
0.1–0.2 mg
5
0.2–0.4 mg
14
0.4–0.6 mg
22
0.6–1 mg
11
1–2 mg
2
2–3 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing14stacking42side effects30melanotan ii8

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 44% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 18 days · Based on 319 repeat reporters

Sources (6)

Published sources linked on the Melanotan I and Melanotan II wiki pages.

  1. PubMed

    Afamelanotide for erythropoietic protoporphyria

    Langendonk JG, Balwani M, Anderson KE, et al. N Engl J Med. 2015

    Source
    Wiki study page →
  2. PubMed

    Targeting the central melanocortin system for the treatment of metabolic disorders

    Sweeney P, Gimenez LE, Hernandez CC, et al. Nature reviews. Endocrinology. 2023

    Source
    Wiki study page →
  3. PubMed

    LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs

    Mestria S, Odoardi S, Frison G, et al. Drug testing and analysis. 2021

    Source
    Wiki study page →
  4. PubMed

    Melanotan II injection resulting in systemic toxicity and rhabdomyolysis

    Nelson ME, Bryant SM, Aks SE. Clinical toxicology (Philadelphia, Pa.). 2012

    Source
    Wiki study page →